300 related articles for article (PubMed ID: 11016595)
1. Alleviation of renal disease and lymphadenopathy in MRL-Fasp(lrcg)/Fas(lprcg) (MR-lpr(cg)) mice neonatally infected with mouse mammary tumor virus encoding superantigen strongly reactive with TCR Vbeta8.2 element.
Matsuzawa A; Yasuda T; Zhang Y; Nagase H; Yoshimoto T; Kimura M; Tsubura A
Viral Immunol; 2000; 13(3):297-311. PubMed ID: 11016595
[TBL] [Abstract][Full Text] [Related]
2. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
3. A pivotal role of cell-bound but not soluble CD4 molecules in full development of lupus-like manifestations in MRL-Fas(lprcg)/Fas(lprcg) mice.
Zhang Y; Yasuda T; Wang CR; Yoshimoto T; Nagase H; Takamoto M; Tsubura A; Kimura M; Matsuzawa A
Clin Exp Immunol; 2000 Oct; 122(1):124-32. PubMed ID: 11012628
[TBL] [Abstract][Full Text] [Related]
4. Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen.
Wrona TJ; Lozano M; Binhazim AA; Dudley JP
J Virol; 1998 Jun; 72(6):4746-55. PubMed ID: 9573239
[TBL] [Abstract][Full Text] [Related]
5. Non-exclusive Fas control and age dependence of viral superantigen-induced clonal deletion in lupus-prone mice.
Papiernik M; Pontoux C; Golstein P
Eur J Immunol; 1995 Jun; 25(6):1517-23. PubMed ID: 7542196
[TBL] [Abstract][Full Text] [Related]
6. T cells bearing Vbeta8 are preferentially infected with exogenous mouse mammary tumor virus.
Upragarin N; Nishimura H; Wajjwalku W; Ando Y; Nagafuchi S; Watanabe T; Yoshikai Y
J Immunol; 1997 Sep; 159(5):2189-95. PubMed ID: 9278306
[TBL] [Abstract][Full Text] [Related]
7. Deletion of CD4+ T cells by mouse mammary tumor virus (FM) superantigen with broad specificity of T cell receptor beta-chain variable region.
Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H
Virology; 1996 Sep; 223(2):387-91. PubMed ID: 8806576
[TBL] [Abstract][Full Text] [Related]
8. Nephritogenicity of the lprcg gene on the MRL background.
Kimura M; Ogata Y; Shimada K; Wakabayashi T; Onoda H; Katagiri T; Matsuzawa A
Immunology; 1992 Jul; 76(3):498-504. PubMed ID: 1526655
[TBL] [Abstract][Full Text] [Related]
9. Characterization of mouse mammary tumour virus-induced migration of lymphoid cells into lymph nodes.
Matsuzawa A; Yasuda T; Sakamoto S; Nagase H; Nakano H; Yoshimoto T
Scand J Immunol; 2001 Jun; 53(6):553-62. PubMed ID: 11422903
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
[TBL] [Abstract][Full Text] [Related]
11. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
Kikawada E; Lenda DM; Kelley VR
J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
[TBL] [Abstract][Full Text] [Related]
12. B and T cells are required for mouse mammary tumor virus spread within the mammary gland.
Golovkina TV; Dudley JP; Ross SR
J Immunol; 1998 Sep; 161(5):2375-82. PubMed ID: 9725233
[TBL] [Abstract][Full Text] [Related]
13. Maternal transfer of infectious mouse mammary tumor retroviruses does not depend on clonal deletion of superantigen-reactive V beta 14+ T cells.
Penninger JM; Wallace VA; Timms E; Mak TW
Eur J Immunol; 1994 May; 24(5):1102-8. PubMed ID: 8181521
[TBL] [Abstract][Full Text] [Related]
14. A V beta 8.2-specific superantigen from exogenous mouse mammary tumor virus carried by FM mice.
Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H
Eur J Immunol; 1994 Jul; 24(7):1612-9. PubMed ID: 7913038
[TBL] [Abstract][Full Text] [Related]
15. CD4 expression is important but not essential for infection with exogenous mouse mammary tumor virus.
Ando Y; Wajjwalku W; Kishihara K; Arai T; Niimi N; Hiromatsu K; Morishima T; Yoshikai Y
Immunobiology; 1996 Aug; 195(3):376-84. PubMed ID: 8877410
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
17. Initial stages of mammary tumor virus infection are superantigen independent.
Pobezinskaya Y; Chervonsky AV; Golovkina TV
J Immunol; 2004 May; 172(9):5582-7. PubMed ID: 15100301
[TBL] [Abstract][Full Text] [Related]
18. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity.
Papiernik M; do Carmo Leite-de-MoraesM ; Pontoux C; Joret AM; Rocha B; Penit C; Dy M
J Immunol; 1997 May; 158(10):4642-53. PubMed ID: 9144476
[TBL] [Abstract][Full Text] [Related]
19. Immunological characterization of C3H mice congenic for Fas(lprcg), C3h/HeJ-Fas(lprcg)/Fas(lprcg).
Yasuda T; Zhang Y; Nagase H; Kaneko T; Sayama K; Hashimoto H; Matsuzawa A
Lab Anim; 2000 Jan; 34(1):46-55. PubMed ID: 10759366
[TBL] [Abstract][Full Text] [Related]
20. A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus.
Maillard I; Erny K; Acha-Orbea H; Diggelmann H
Eur J Immunol; 1996 May; 26(5):1000-6. PubMed ID: 8647159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
